Positions

Overview

  • Dr. Lebensburger is Director, Pediatric Hematology Section in the Division of Pediatric Hematology Oncology. He has expertise in sickle cell disease and hemoglobinopathies, red cell disorders, ITP, bleeding disorders, blood clotting disorders, bone marrow failure syndromes, and general hematology.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis.Medical and Pediatric Oncology.  65:e27420. 2018
    2018 Red blood cell transfusion therapy for sickle cell patients with frequent painful events.Medical and Pediatric Oncology.  65:e27423. 2018
    2018 Outcomes of febrile events in pediatric patients with sickle cell anemia.Medical and Pediatric Oncology.  65:e27379. 2018
    2018 Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.American Journal of Hematology2018
    2018 Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthoodMedical and Pediatric Oncology.  65. 2018
    2018 Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.Journal of Allergy and Clinical Immunology2018
    2018 Management of severe chronic pain with methadone in pediatric patients with sickle cell disease.Medical and Pediatric Oncology.  65:e27084. 2018
    2018 Outcomes in Mild to Moderate Isolated Thrombocytopenia.Pediatrics.  142. 2018
    2018 Acute Kidney Injury during Parvovirus B19-Induced Transient Aplastic Crisis in Sickle Cell Disease.American Journal of Hematology2018
    2018 Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference.British Journal of Haematology.  181:145-148. 2018
    2017 Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.Pediatric Nephrology.  32:1565-1573. 2017
    2017 Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.Pediatric Nephrology.  32:1451-1456. 2017
    2017 Cranial epidural hematomas: A case series and literature review of this rare complication associated with sickle cell disease.Medical and Pediatric Oncology.  64. 2017
    2017 Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.American Journal of Hematology.  92:E81-E83. 2017
    2017 Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease.Medical and Pediatric Oncology.  64:113-120. 2017
    2016 Severe anemia early in life as a risk factor for sickle-cell kidney disease.Blood.  129:385-387. 2016
    2016 Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices.Redox Biology.  9:167-177. 2016
    2016 Prevalence of acute kidney injury during pediatric admissions for acute chest syndrome.Pediatric Nephrology.  31:1363-1368. 2016
    2016 Maintaining High Level of Care at Satellite Sickle Cell Clinics.Journal of Health Care for the Poor and Underserved.  27:280-292. 2016
    2015 Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov.Clinical Trials.  12:575-583. 2015
    2015 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.Medical and Pediatric Oncology.  62:1427-1436. 2015
    2015 Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.Journal of Neurosurgery: Pediatrics.  16:64-73. 2015
    2015 Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease.International journal of hematology & therapy.  1. 2015
    2015 Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia.Journal of Blood Medicine.  6:285-290. 2015
    2015 Patient-centered approach to designing sickle cell transition education.Journal of Pediatric Hematology/Oncology.  37:43-47. 2015
    2015 Understanding and improving health education among first-time parents of infants with sickle cell anemia in Alabama: a mixed methods approach.Journal of Pediatric Hematology/Oncology.  37:35-42. 2015
    2015 Understanding and improving health education among first-time parents of infants with sickle cell anemia in alabama: A mixed methods approachJournal of Pediatric Hematology/Oncology.  37:35-42. 2015
    2014 Social skills and executive function among youth with sickle cell disease: a preliminary investigation.Journal of Pediatric Psychology.  39:493-500. 2014
    2014 Ferritin and LIC: predicting liver injury in children with sickle cell.Journal of Pediatric Gastroenterology and Nutrition.  58:387-390. 2014
    2013 Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.Medical and Pediatric Oncology.  60:1333-1337. 2013
    2013 Hydroxyurea treatment of children with hemoglobin SC disease.Medical and Pediatric Oncology.  60:323-325. 2013
    2012 Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.Medical and Pediatric Oncology.  59:675-678. 2012
    2012 Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.Blood.  119:1915-1921. 2012
    2012 Barriers in transition from pediatrics to adult medicine in sickle cell anemia.Journal of Blood Medicine.  3:105-112. 2012
    2011 Laboratory and clinical correlates for magnetic resonance imaging (MRI) abnormalities in pediatric sickle cell anemia.Journal of Child Neurology.  26:1260-1264. 2011
    2011 Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.American Journal of Hematology.  86:430-432. 2011
    2011 What is the evidence for using hydroxyurea for secondary stroke prevention?Hematology online (ASH).  2011:440-442. 2011

    Research Overview

  • Dr. Lebensburger has received funding from the National Institutes of Health, American Society of Hematology, Patient Centered Outcomes Research Institute to study sickle cell organ complications, transition of care, and patient education. He is also an investigator for the ITP Consortium of North America.
  • Investigator On

  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2020
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Transforming Pediatric Oncology Healthcare Through Family Navigation  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2017 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2017
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee 2015 - 2016
  • CCOP Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2015
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP 2014
  • Pediatric Trial Network-Hydroxyuea/To 4  awarded by Duke University 2012 - 2014
  • COG Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2014
  • Private Grant  awarded by TERUMO BCT, INC. 2012 - 2013
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University 2011 - 2013
  • Private Grant  awarded by GLYCOMIMETICS, INC. 2010 - 2013
  • Baby HUG Follow-up Study II: Clinical Studies  awarded by University of Texas Southwestern Medical Center at Dallas 2012
  • Teaching Overview

  • Dr. Lebensburger teaches a wide array of courses in Hematology to Medical students, Pediatric residents, and pediatric Hematology Oncology Fellows. Dr. Lebensburger also serves as faculty at the American Society of Hematology Clinical Research Training Institute where he mentors young leaders in the field throughout the country.
  • Education And Training

  • Doctor of Osteopathy in Osteopathic Medicine / Osteopathy, Nova Southeastern University
  • Full Name

  • Jeffrey Lebensburger
  • Blazerid

  • jlebensb